WO2010129509A1 - Vinyl indazolyl compounds - Google Patents
Vinyl indazolyl compounds Download PDFInfo
- Publication number
- WO2010129509A1 WO2010129509A1 PCT/US2010/033487 US2010033487W WO2010129509A1 WO 2010129509 A1 WO2010129509 A1 WO 2010129509A1 US 2010033487 W US2010033487 W US 2010033487W WO 2010129509 A1 WO2010129509 A1 WO 2010129509A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- inhibition
- cells
- vinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Fibroblast growth factor has been recognized as an important mediator of many physiological processes, such as morphogenesis during development and angiogenesis.
- the fibroblast growth factor receptor (FGFR) family consists of four members (FGFR 1-FGFR4), which are glycoproteins composed of extracellular immunoglobulin (Ig)-like domains, a hydrophobic transmembrane region and a cytoplasmic part containing a tyrosine kinase domain. FGF binding leads to FGFR dimerization, followed by receptor autophosphorylation and activation of downstream signaling pathways. Receptor activation is sufficient for the recruitment and activation of specific downstream signaling partners that participate in the regulation of diverse processes such as cell growth, cell metabolism and cell survival.
- Ig immunoglobulin
- the FGF/FGFR signaling pathway has pleiotropic effects on many biological processes critical to tumor cell proliferation, migration, invasion, and angiogenesis.
- Vinyl indazoles are known in the art for the treatment of cancer. See for example, WO0210137 and WO2003101968.
- FGFR inhibitors are also known in the art. See for example, WO2002022598.
- the present invention provides novel vinyl indazolyl compounds believed to have clinical use for treatment of proliferative disorders such as cancer and particularly in disorders mediated by FGF and/or FGFR dysregulation.
- certain compounds of the present invention have superior FGFRl and FGFR3 potency compared to certain previously known FGFR inhibitors.
- the present invention provides a compound which is (E)-2-(4-(2-(5-(l-(3,5- dichloropyridin-4-yl)ethoxy)- lH-indazol-3-yl)vinyl)- lH-pyrazol- 1 -yl)ethanol or a pharmaceutically acceptable salt thereof.
- the present invention also provides the compound which is (R)-(E)-2-(4-(2- (5 -( 1 -(3 ,5 -dichloropyridin-4-yl)ethoxy)- 1 H-indazol-3 -yl)vinyl)- 1 H-pyrazol- 1 - yl)ethanol or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating cancer wherein the cancer is selected from the group consisting of breast cancer, non-small cell lung (NSCL) cancer, bladder cancer, gastric cancer, pancreatic cancer, prostate cancer, colon cancer, multiple myeloma, liver cancer, melanoma, head and neck cancer, thyroid cancer, renal cell cancer, glioblastoma, and testicular cancer in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound or salt of the present invention.
- This invention also provides pharmaceutical compositions comprising a compound or salt of the present invention in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients. In a particular embodiment the composition further comprises one or more other therapeutic agents.
- This invention also provides a compound or salt of the present invention for use in therapy. Additionally, this invention provides use of a compound or salt of the present invention in the manufacture of a medicament for treating cancer.
- these cancers are selected from the group consisting of breast cancer, lung cancer, bladder cancer, gastric cancer, pancreatic cancer, prostate cancer, colon cancer, multiple myeloma AML, liver cancer, melanoma, head and neck cancer, thyroid cancer, renal cell cancer, glioblastoma, and testicular cancer.
- the cancers are selected from the group consisting of breast cancer, non- small cell lung cancer, bladder cancer, gastric cancer, pancreatic cancer, prostate cancer, colon cancer, multiple myeloma, liver cancer, melanoma, head and neck cancer, thyroid cancer, renal cell cancer, glioblastoma, and testicular cancer.
- the cancer is non-small cell lung cancer.
- the cancer is gastric cancer.
- the cancer is multiple myeloma.
- this invention provides a pharmaceutical composition for treating cancer selected from the group consisting of breast cancer, non-small cell lung cancer, bladder cancer, gastric cancer, pancreatic cancer, prostate cancer, colon cancer, multiple myeloma, liver cancer, melanoma, head and neck cancer, thyroid cancer, renal cell cancer, glioblastoma, and testicular cancer comprising a compound or salt of the present invention as an active ingredient.
- cancer selected from the group consisting of breast cancer, non-small cell lung cancer, bladder cancer, gastric cancer, pancreatic cancer, prostate cancer, colon cancer, multiple myeloma, liver cancer, melanoma, head and neck cancer, thyroid cancer, renal cell cancer, glioblastoma, and testicular cancer comprising a compound or salt of the present invention as an active ingredient.
- racemic (E)-2-(4-(2-(5-(l-(3,5- dichloropyridin-4-yl)ethoxy)-lH-indazol-3-yl)vinyl)-lH-pyrazol-l-yl)ethanol can be made essentially as described for (R)-(E)-2-(4-(2-(5-(l-(3,5-dichloropyridin-4- yl)ethoxy)-lH-indazol-3-yl)vinyl)-lH-pyrazol-l-yl)ethanol starting from racemic 1- (3,5-dichloropyridin-4-yl)ethanol in place of (S)-I -(3,5-dichloropyridin-4-yl)ethanol.
- (E)-2-(4-(2-(5-(l-(3,5- dichloropyridin-4-yl)ethoxy)- 1 H-indazol-3 -yl)vinyl)- 1 H-pyrazol- 1 -yl)ethanol contains one chiral center. It is preferred that (E)-2-(4-(2-(5-(l-(3,5-dichloropyridin- 4-yl)ethoxy)-lH-indazol-3-yl)vinyl)-lH-pyrazol-l-yl)ethanol exists as a single enantiomer.
- the single enantiomer may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques. Alternatively, the single enantiomer may be isolated from mixtures by standard chiral chromatographic or crystallization techniques. It will be understood by the skilled reader that all of the compounds of the present invention are capable of forming salts.
- the compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
- Such pharmaceutically acceptable acid addition salts and common methodology for preparing them are well known in the art. See, e.g., P.
- the compounds of the present invention can be prepared as illustrated in the preparations and examples below.
- the activating mutations in the FGFR kinase domain have been found in several types of tumors, including breast, NSCLC, bladder, gastric, prostate, colon, and multiple myeloma. Genomic amplification of FGFR locus was also detected in many breast, gastric, and multiple myeloma cancer patients. Over-expression of FGFRs and FGFs has also been found in many different types of tumors such as bladder, multiple myeloma, prostate, and lung cancers. Other cancers that might benefit from FGFR family pathway inhibitor therapy include AML, liver cancer, melanoma, head and neck cancer, thyroid cancer, pancreatic cancer, renal cell cancer, glioblastoma, and testicular cancer.
- FGFs and FGFRs are also key regulators of angiogenesis, especially during tumor growth.
- the FGF/FGFR axis also plays an important role in augmenting other tumor stromal cells such as cancer associated fibroblasts. Up-regulation of FGFs also leads to resistance to anti- angiogenic and other chemo-therapies.
- small molecule inhibitors of FGFRs have demonstrated anti-tumor activities in several preclinical tumor models and are being explored in the clinic. Taken together, the FGF/FGFR pathway is essential to several important cellular processes in cancer cells. For these reasons, therapies targeting FGFRs and/or FGF signaling may affect both the tumor cells directly and tumor angiogenesis.
- FGFRl Enzyme Assay (Filter Binding)
- the FGFR3 Enzyme Assay (Filter Binding)
- FGF9 induced p-ERK in RT- 112 cell based assay (in the presence of BSA)
- the AlphaScreen SureFire Detection of ERK phosphorylation (Thr202/Tyr204) in Human Umbilical Vein Endothelial Cells (HUVEC) cell based assays
- FGFR in vivo target inhibition assay and RTl 12 human bladder and other cancer xenograft Models.
- FGFRl and FGFR3 Enzyme Assay (Filter Binding)
- FGFRl or FGFR3 kinase (0.15 ng/ ⁇ L human FGFRl or 0.32 ng/ ⁇ L human FGFR3) is incubated in 50 ⁇ L of a buffer containing 10 mM 4-(2-hydroxyethyl)- 1 - piperazineethane-sulfonic acid (HEPES ) pH 7.5, 8 mM tris(hydroxymethyl)aminomethane (Tris-HCl), pH 7.5, 5.0 mM dithiothreitol (DTT), 10.0 ⁇ M adenosine triphosphate (ATP), 10 mM MnCl 2 , 150 mM NaCl, 0.01% TRITON® X-100, 0.5 ⁇ Ci 33 P-ATP, and 0.05 ⁇ g/ ⁇ L Poly(Glu-Tyr).
- HEPES 4-(2-hydroxyethyl)- 1 - piperazineethane-sulfonic acid
- Tris-HCl tris(hydroxy
- the reaction is carried out in a volume of 50 ⁇ L at RT for 30 minutes and then quenched by adding 130 ⁇ L of 10% H 3 PO 4 .
- the reaction 120 ⁇ L is transferred to a 96 well 1.0 ⁇ m glass fiber filter plate, incubated at RT for 20-30 minutes and then washed 3x on a
- TM of MicroScint 20 (Packard) and then counted on a Wallac Micobeta counter.
- compounds are provided as 10 mM stocks in dimethyl sulfoxide (DMSO).
- DMSO dimethyl sulfoxide
- Compounds are serially diluted 1 :3 in 20% DMSO to create a 10 point concentration-response curve and diluted 1 :5 (20 ⁇ M to 0.001 ⁇ M final in 4% final DMSO concentration) into the reaction plate prior to addition of the reaction mixture in the filter plate to determine compound activity.
- Control wells contain 4% DMSO only while the baseline is established by control wells containing 0.1 M ethylenediaminetetraacetic acid (EDTA).
- EDTA ethylenediaminetetraacetic acid
- the percent inhibition values for each of the 10 concentrations are calculated from control wells on each plate and the 10-point concentration response data are subsequently analyzed using ActivityBase software (IDBS) using a 4-parameter logistic equation and absolute IC 50 values estimated from the resulting curve fit.
- IDBS ActivityBase software
- the FGFRl and FGFR3 enzyme assays have Minimum Significant Ratios (MSR) for the estimated IC50 of 1.38 and 1.47, respectively.
- MSR Minimum Significant Ratios
- the IC 50 results for Example 1 for FGFRl and FGFR3 in these assays are estimated to be 0.0077 and 0.0064 ⁇ M, respectively. This data demonstrates that certain compounds of the present invention are potent FGFRl and FGFR3 enzyme inhibitors.
- FGF9 induced p-ERK with BSA Human RTl 12 bladder carcinoma cells are seeded at a density of 5,000 cells per well in 100 ⁇ L RPMI 1640 (Gibco 11875-085) supplemented with 10% fetal bovine serum (FBS, Gibco 10082-147) and 1% of a penicillin/streptomycin solution (Gibco 15140-122) in CELLBIND® 96 well plates (Corning 3340) and incubated overnight at 37 0 C. The next morning the growth medium is removed and replaced with 100 ⁇ L RPMI 1640 supplemented with 20 mg/mL bovine serum albumin (BSA).
- BSA bovine serum albumin
- Cells are fixed by the addition of 30 ⁇ L of a 25% formaldehyde solution in phosphate buffered saline (PBS) (3.7% formaldehyde final concentration), and incubated 30 minutes at RT. Cells are washed 3x with PBS, followed by the addition of 100 ⁇ L of cold methanol and incubated for 30 minutes at -20 0 C. The methanol is removed and the cells are treated with PBS containing 0.1% TRITON® X-100 (PBST), washed 3x with PBS, and incubated 15 minutes at RT.
- PBS phosphate buffered saline
- Cells are then incubated overnight at 4 0 C with gentle shaking in 50 ⁇ L of a 1 :400 dilution of the p-p44/42 MAPK primary antibody (Cell Signaling 9101S) in PBS supplemented with 2% BSA, 0.01% Phosphatase Inhibitor Cocktail 1 (Sigma P2850), 0.01% Phosphatase Inhibitor Cocktail 2 (Sigma P5726), and 0.01% Protease Inhibitor Cocktail (Sigma P8340).
- the total mean intensity for pERK/well using the Alexa 488 values is subsequently converted to percent inhibition using values obtained from MIN (10 ⁇ M positive control compound in DMSO) and MAX (DMSO alone) controls run on the same plate.
- the percentage inhibition values and the 10-point concentration response data are subsequently analyzed using a 4-parameter sigmoidal dose response equation and relative IC50 values are estimated from the resulting curve.
- the FGF9 induced p-ERK with BSA assay has a Minimum Significant Ratio (MSR) for the estimated IC50 of 2.7.
- the IC50 for Example 1 in this assay is estimated to be 0.0004 ⁇ M.
- Umbilical Vein Endothelial Cells The effect of compounds on the inhibition of FGF receptor 1 is measured by monitoring the phosphorylation of ERK (pERK) in response to basic-Fibroblast growth factor (b-FGF) stimulation in Human Umbilical Endothelial cells (HUVEC).
- the levels of pERK formed are measured using the ALPHASCREEN® SUREFIRE ® system (TGR Biosciences, TGRES50K). This is a homogeneous assay format utilizing the immuno-sandwich capture of the phosphorylated analyte followed by detection using antibody-coated ALPHASCREEN® beads (Perkin Elmer) to generate an amplified signal.
- HUVEC cells are recovered and maintained in growth medium consisting of endothelial cell basal medium (Clonetics, CC-3132) supplemented with 10% FBS 0.4% bovine brain extract 0.1% hydrocortisone, 0.1% gentamicin sulfate amphotericin-B, and 0.1% epidermal growth facter, human recombination until passage 7.
- endothelial cell basal medium Clonetics, CC-3132
- bovine brain extract 0.1% hydrocortisone, 0.1% gentamicin sulfate amphotericin-B, and 0.1% epidermal growth facter, human recombination until passage 7.
- FBS endothelial cell basal medium
- bovine brain extract 0.1% hydrocortisone
- 0.1% gentamicin sulfate amphotericin-B 0.1% epidermal growth facter, human recombination until passage 7.
- epidermal growth facter human recombination until passage 7.
- cells are harvested
- EBM endothelial cell basal
- BSA endothelial cell basal
- 20 ⁇ M of 3x serially diluted compounds in starvation medium for 1 hour at 37 0 C.
- cells are stimulated with 50 ⁇ L b-FGF (Sigma, F0291, final b-FGF concentration 50 ng/mL) at 37 0 C for 15 minutes.
- the plate is sealed and incubated at RT for 2 hours with gentle shaking and then read on Perkin Elmer EnVision plate reader equipped with a TurboModule using standard ALPHASCREEN® settings (Ex680 nm and Em 52 o-6 2 ⁇ nm )-
- the emission data is converted to percent inhibition determined from MAX (DMSO alone) and MIN (10 ⁇ M positive control compound in DMSO) controls on each plate and ten-point compound concentration data are then fit to a four-parameter logistic equation using ACTIVITYBASE® 4.0 and the IC 50 is estimated.
- the ALPHASCREEN® SUREFIRE® Detection of ERK phosphorylation ((Thr202/Tyr204) assay has a Minimum Significant Ratio (MSR) for the IC 50 of 2.1.
- MSR Minimum Significant Ratio
- the IC50 of Example 1 in this assay is estimated to be 0.0006 ⁇ M.
- mice Female nude mice (CDl/nu/nu) are acclimated for 1 week prior to treatment. Animals are grouped into positive control, negative control and compound treatment groups. Compound (formulated in 10% Acacia), positive control (10% Acacia), and negative control (10% Acacia) are administered by oral gavage. Compound doses are in the range of 0.15 to 25 mg/kg. After 2 hours, the compound treatment group and the positive control group are treated with freshly prepared mouse bFGF (6 ⁇ g/animal, Biosource PMG0033) in saline administered intravenously. The negative control group is treated with saline administered intravenously. Mice are sacrificed 10 minutes post intravenous dose.
- Animal heart is harvested and homogenized for 10 seconds in 300 ⁇ L of ice cold lysis buffer (RIPA; Boston BioProduct BP-115) containing 1 : 100 diluted of inhibitors (phosphotase inhibitor cocktail I Sigma P2850; phosphotase inhibitor cocktail II Sigma P5726 and protease inhibitor cocktail Sigma P8340). Homogenates are centrifuged at 14,000 RPM for 15 minutes and supernatants are transferred to a 96-well plate. Protein level is determined by COOMASSIE PLUSTM protein assay method (Pierce # 1856210). Assay procedures are the same per manufacturer's recommendation (see instruction booklet included in the assay kit).
- Heart tissue homogenates are analyzed using MSD® phospho-Erk ELISA (Meso Scale Discovery, catalog number N4 ICB-I) to determine tissue phospho-Erk level.
- MSD® phospho-Erk ELISA Meso Scale Discovery, catalog number N4 ICB-I
- the ELISA procedures are the same per manufacturer's recommendation (see instruction booklet included in the assay kit; the only modification is that 0.2% sodium dodecyl sulfate is added to the lysis buffer).
- Positive control is used as minimum phospho-Erk inhibition (0%) and the negative control is used as maximum phospho-Erk inhibition (100%).
- Percent inhibition of compound treated groups is calculated relative to the maximum and minimum inhibition groups.
- TEC 9 0 is calculated from a dose response study and is the concentration necessary to achieve 90% inhibition at this time point.
- the compound of Example 1 has an estimated TEC90 of 28 nM.
- This data demonstrates that certain compounds of the present invention are potent inhibitors of bFGF induced ERK phosphorylation in vivo.
- VEGF is used to induce Kdr autophosphorylation ⁇ VEGF (6 ug/animal, R & D Systems 493-MV/CF).
- Heart tissues are collected and homogenized as described above.
- the resulting homogenates are analyzed using MSD® phospho-Kdr ELISA (Meso Scale Discovery, catalog number N4 IZA-I) to determine tissue phospho-Kdr level.
- the ELISA procedures are the same per manufacturer's recommendation (see instruction booklet included in the assay kit; the only modification is that 0.2% sodium dodecyl sulfate is added to the lysis buffer).
- the positive control group is treated with VEGF 96 ug/animal) in saline administered intravenously (as minimum p-KDR inhibition of 0%).
- the negative control group is treated with saline administered intravenously (as maximum p-KDR inhibition of 100%). Percent inhibition of compound treated groups is calculated relative to the maximum and minimum inhibition groups.
- TED50 is calculated from a dose response study and is the dose necessary to achieve 50% inhibition at this time point.
- the compound of Example 1 has an estimated TED 5 O of 1.34 mg/kg.
- the TEC 9 0 is calculated from a dose response study and is the concentration necessary to achieve 90% inhibition at this time point.
- the compound of Example 1 has an estimated TEC 9 0 of 252 nM.
- Human bladder cancer cells RTl 12 European Collection of Cell Cultures
- human multiple myeloma cells OPM-2 German Collection of Microorganisms and Cell Cultures
- human non-small cell lung cancer (NSCL) cells NCI-H460 (American Type Culture Collection)
- human pancreatic cancer cells BxPC- 3 American Type Culture Collection
- Example 1 demonstrated dose dependent anti-tumor activity in several xenograft tumor models.
- NSCLC tumor model NSCLC tumor model (NCI-H460), when dosed at 3 mg/kg (QD for 17 days), 46% inhibition was achieved; when dosed at 3 mg/kg (BID for 17 days), 69% inhibition was achieved.
- pancreatic tumor model BxPC-3
- BxPC-3 pancreatic tumor model
- the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral or intravenous administration. Such pharmaceutical compositions and processes for preparing same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (D. Troy, et al, eds., 21 st ed., Lippincott Williams & Wilkins, 2005).
- the compounds of the present invention are generally effective over a wide dosage range. For example, dosages per day normally fall within the range of about 0.5 to about 100 mg/kg of body weight.
- dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage range is not intended to limit the scope of the invention in any way.
- the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011011342A MX2011011342A (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds. |
EA201171367A EA018149B1 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
SI201030191T SI2427449T1 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
KR1020117026320A KR101373910B1 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
NZ595553A NZ595553A (en) | 2009-05-07 | 2010-05-04 | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol |
ES10717402T ES2408117T3 (en) | 2009-05-07 | 2010-05-04 | Vinyl Indazolyl Compounds |
RS20130207A RS52795B (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
UAA201112804A UA104756C2 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
DK10717402.1T DK2427449T3 (en) | 2009-05-07 | 2010-05-04 | VINYLINDAZOLYL COMPOUNDS |
CN201080020264.3A CN102421769B (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
AU2010246114A AU2010246114B2 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
SG2011081627A SG175909A1 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
JP2012509889A JP5555314B2 (en) | 2009-05-07 | 2010-05-04 | Vinylindazolyl compounds |
EP10717402A EP2427449B1 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
BRPI1013748A BRPI1013748A2 (en) | 2009-05-07 | 2010-05-04 | "vinyl indazolyl compounds" |
MA34312A MA33244B1 (en) | 2009-05-07 | 2010-05-04 | VINYLINDAZOLYL COMPOUNDS |
MEP-2013-32A ME01462B (en) | 2009-05-07 | 2010-05-04 | Vinyl indazol yl compounds |
PL10717402T PL2427449T3 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
CA2760535A CA2760535C (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
TNP2011000545A TN2011000545A1 (en) | 2010-02-04 | 2011-10-25 | Vinyl indazolyl compounds |
IL216004A IL216004A (en) | 2009-05-07 | 2011-10-27 | Vinyl indazolyl compounds and pharmaceutical compositions comprising them |
HK12103968.8A HK1163665A1 (en) | 2009-05-07 | 2012-04-20 | Vinyl indazolyl compounds |
HRP20130323AT HRP20130323T1 (en) | 2009-05-07 | 2013-04-10 | Vinyl indazolyl compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17629009P | 2009-05-07 | 2009-05-07 | |
US61/176,290 | 2009-05-07 | ||
US30141610P | 2010-02-04 | 2010-02-04 | |
US61/301,416 | 2010-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010129509A1 true WO2010129509A1 (en) | 2010-11-11 |
Family
ID=42238704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/033487 WO2010129509A1 (en) | 2009-05-07 | 2010-05-04 | Vinyl indazolyl compounds |
Country Status (35)
Country | Link |
---|---|
US (1) | US8268869B2 (en) |
EP (1) | EP2427449B1 (en) |
JP (1) | JP5555314B2 (en) |
KR (1) | KR101373910B1 (en) |
CN (1) | CN102421769B (en) |
AR (1) | AR078411A1 (en) |
AU (1) | AU2010246114B2 (en) |
BR (1) | BRPI1013748A2 (en) |
CA (1) | CA2760535C (en) |
CL (1) | CL2011002781A1 (en) |
CO (1) | CO6450624A2 (en) |
CR (1) | CR20110580A (en) |
DK (1) | DK2427449T3 (en) |
EA (1) | EA018149B1 (en) |
EC (1) | ECSP11011441A (en) |
ES (1) | ES2408117T3 (en) |
HK (1) | HK1163665A1 (en) |
HN (1) | HN2011002809A (en) |
HR (1) | HRP20130323T1 (en) |
IL (1) | IL216004A (en) |
JO (1) | JO2860B1 (en) |
MA (1) | MA33244B1 (en) |
ME (1) | ME01462B (en) |
MX (1) | MX2011011342A (en) |
MY (1) | MY160390A (en) |
NZ (1) | NZ595553A (en) |
PE (2) | PE20120812A1 (en) |
PL (1) | PL2427449T3 (en) |
PT (1) | PT2427449E (en) |
RS (1) | RS52795B (en) |
SG (1) | SG175909A1 (en) |
SI (1) | SI2427449T1 (en) |
TW (1) | TWI382982B (en) |
UA (1) | UA104756C2 (en) |
WO (1) | WO2010129509A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012047699A1 (en) * | 2010-10-05 | 2012-04-12 | Eli Lilly And Company | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |
WO2013133351A1 (en) | 2012-03-08 | 2013-09-12 | アステラス製薬株式会社 | Novel fgfr3 fusion product |
CN103819396A (en) * | 2014-02-26 | 2014-05-28 | 四川大学 | Synthesis method of chiral 1-(3,5-dichloropyridine-4-yl)-ethanol |
WO2014151734A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10214515B2 (en) | 2015-08-20 | 2019-02-26 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Substituted pyrazoles as inhibitors of fibroblast growth factor receptor |
US10544144B2 (en) | 2016-06-06 | 2020-01-28 | Shanghai Allist Pharmaceutical And Medical Technol | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof |
US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3778644A2 (en) | 2014-12-23 | 2021-02-17 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
WO2021138391A1 (en) * | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
EP4056558A4 (en) * | 2019-11-06 | 2023-12-27 | Jinan University | Indazole compound, pharmaceutical composition of same, and applications thereof |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11920138B2 (en) | 2012-07-24 | 2024-03-05 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105906621A (en) * | 2015-04-06 | 2016-08-31 | 四川百利药业有限责任公司 | Ethanol compound used as FGFR inhibitor |
WO2016187767A1 (en) * | 2015-05-25 | 2016-12-01 | Hutchison Medipharma Limited | Pharmaceutical compositions and use thereof |
EP3333157B1 (en) * | 2015-08-07 | 2020-12-23 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Vinyl compounds as fgfr and vegfr inhibitors |
WO2022033472A1 (en) * | 2020-08-11 | 2022-02-17 | 河南迈英诺医药科技有限公司 | Fgfr inhibitor compound and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010137A2 (en) * | 2000-07-31 | 2002-02-07 | Signal Pharmaceuticals, Inc. | Indazole derivatives as jnk inhibitors |
EP1510516A1 (en) * | 2002-05-31 | 2005-03-02 | Eisai Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1650203T3 (en) | 2000-09-11 | 2008-06-02 | Novartis Vaccines & Diagnostic | Quinolinone derivatives as tyrosine kinase inhibitors |
EP1447405A4 (en) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors |
DE10342503A1 (en) * | 2003-09-12 | 2005-04-14 | Merck Patent Gmbh | Benzyl-Benzimidazolylderivate |
EP1753763B1 (en) | 2004-05-26 | 2008-08-13 | Pfizer Limited | Indazole and indolone derivatives and their use as pharmaceuticals |
WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
JP2009531274A (en) * | 2005-12-07 | 2009-09-03 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Kinase-inhibiting pyrrolopyridine compounds |
DK2120932T3 (en) | 2006-12-20 | 2014-10-13 | Nerviano Medical Sciences Srl | INDAZOL DERIVATIVES AS KINase INHIBITORS FOR TREATMENT OF CANCER |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
BRPI0812450A2 (en) | 2007-06-05 | 2019-09-24 | Schering Corp | polycyclic indazole derivatives and their use as erk inhibitors for cancer treatment |
DE102007028521A1 (en) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
EP2265270A1 (en) * | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
-
2010
- 2010-04-27 AR ARP100101403A patent/AR078411A1/en unknown
- 2010-04-27 JO JO2010130A patent/JO2860B1/en active
- 2010-04-29 TW TW099113702A patent/TWI382982B/en not_active IP Right Cessation
- 2010-05-04 RS RS20130207A patent/RS52795B/en unknown
- 2010-05-04 NZ NZ595553A patent/NZ595553A/en not_active IP Right Cessation
- 2010-05-04 MX MX2011011342A patent/MX2011011342A/en active IP Right Grant
- 2010-05-04 JP JP2012509889A patent/JP5555314B2/en not_active Expired - Fee Related
- 2010-05-04 PE PE2011001877A patent/PE20120812A1/en not_active Application Discontinuation
- 2010-05-04 US US12/773,186 patent/US8268869B2/en not_active Expired - Fee Related
- 2010-05-04 PT PT107174021T patent/PT2427449E/en unknown
- 2010-05-04 CN CN201080020264.3A patent/CN102421769B/en not_active Expired - Fee Related
- 2010-05-04 SG SG2011081627A patent/SG175909A1/en unknown
- 2010-05-04 PL PL10717402T patent/PL2427449T3/en unknown
- 2010-05-04 CA CA2760535A patent/CA2760535C/en not_active Expired - Fee Related
- 2010-05-04 EA EA201171367A patent/EA018149B1/en not_active IP Right Cessation
- 2010-05-04 ES ES10717402T patent/ES2408117T3/en active Active
- 2010-05-04 SI SI201030191T patent/SI2427449T1/en unknown
- 2010-05-04 DK DK10717402.1T patent/DK2427449T3/en active
- 2010-05-04 WO PCT/US2010/033487 patent/WO2010129509A1/en active Application Filing
- 2010-05-04 UA UAA201112804A patent/UA104756C2/en unknown
- 2010-05-04 AU AU2010246114A patent/AU2010246114B2/en not_active Ceased
- 2010-05-04 MY MYPI2011005296A patent/MY160390A/en unknown
- 2010-05-04 BR BRPI1013748A patent/BRPI1013748A2/en not_active IP Right Cessation
- 2010-05-04 ME MEP-2013-32A patent/ME01462B/en unknown
- 2010-05-04 KR KR1020117026320A patent/KR101373910B1/en not_active IP Right Cessation
- 2010-05-04 MA MA34312A patent/MA33244B1/en unknown
- 2010-05-04 EP EP10717402A patent/EP2427449B1/en active Active
- 2010-05-04 PE PE2016000013A patent/PE20160124A1/en not_active Application Discontinuation
-
2011
- 2011-10-21 HN HN2011002809A patent/HN2011002809A/en unknown
- 2011-10-27 IL IL216004A patent/IL216004A/en not_active IP Right Cessation
- 2011-11-04 CO CO11150245A patent/CO6450624A2/en active IP Right Grant
- 2011-11-07 CR CR20110580A patent/CR20110580A/en unknown
- 2011-11-07 CL CL2011002781A patent/CL2011002781A1/en unknown
- 2011-11-07 EC EC2011011441A patent/ECSP11011441A/en unknown
-
2012
- 2012-04-20 HK HK12103968.8A patent/HK1163665A1/en not_active IP Right Cessation
-
2013
- 2013-04-10 HR HRP20130323AT patent/HRP20130323T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010137A2 (en) * | 2000-07-31 | 2002-02-07 | Signal Pharmaceuticals, Inc. | Indazole derivatives as jnk inhibitors |
EP1510516A1 (en) * | 2002-05-31 | 2005-03-02 | Eisai Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
Non-Patent Citations (1)
Title |
---|
S.M. BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF* PHARMACEUTICAL SCIENCES, vol. 66, no. 1, January 1977 (1977-01-01), XP002675560, DOI: doi:10.1002/jps.2600660104 |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012047699A1 (en) * | 2010-10-05 | 2012-04-12 | Eli Lilly And Company | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |
AU2011312485B2 (en) * | 2010-10-05 | 2014-09-04 | Eli Lilly And Company | Crystalline (R) - (E) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1H - indazol - 3 - yl) vinyl) -1 H- pyrazol- 1 -yl) ethanol and its use as FGFR inhibitor |
EA021817B1 (en) * | 2010-10-05 | 2015-09-30 | Эли Лилли Энд Компани | Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol monohydrate |
JP2013538875A (en) * | 2010-10-05 | 2013-10-17 | イーライ リリー アンド カンパニー | Crystalline ((R)-(E) -2- (4- (2- (5- (1- (3,5-dichloropyridin-4-yl) ethoxy) -1H-indazol-3-yl) vinyl)- 1H-pyrazol-1-yl) ethanol and use as FGFR inhibitor |
US8530665B2 (en) | 2010-10-05 | 2013-09-10 | Eli Lilly And Company | Crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol |
US10213427B2 (en) | 2010-12-22 | 2019-02-26 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US10813930B2 (en) | 2010-12-22 | 2020-10-27 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
WO2013133351A1 (en) | 2012-03-08 | 2013-09-12 | アステラス製薬株式会社 | Novel fgfr3 fusion product |
US11840534B2 (en) | 2012-06-13 | 2023-12-12 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US10131667B2 (en) | 2012-06-13 | 2018-11-20 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11053246B2 (en) | 2012-06-13 | 2021-07-06 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11920138B2 (en) | 2012-07-24 | 2024-03-05 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9745311B2 (en) | 2012-08-10 | 2017-08-29 | Incyte Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014151734A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US11505788B2 (en) | 2013-03-15 | 2022-11-22 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US10208296B2 (en) | 2013-03-15 | 2019-02-19 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US10040790B2 (en) | 2013-04-19 | 2018-08-07 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10947230B2 (en) | 2013-04-19 | 2021-03-16 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10450313B2 (en) | 2013-04-19 | 2019-10-22 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN103819396A (en) * | 2014-02-26 | 2014-05-28 | 四川大学 | Synthesis method of chiral 1-(3,5-dichloropyridine-4-yl)-ethanol |
CN103819396B (en) * | 2014-02-26 | 2016-06-15 | 四川大学 | A kind of 1-(3,5-dichloropyridine-4-base of chirality) synthetic method of-ethanol |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3925979A2 (en) | 2014-12-23 | 2021-12-22 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
EP3778644A2 (en) | 2014-12-23 | 2021-02-17 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
US10738048B2 (en) | 2015-02-20 | 2020-08-11 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10016438B2 (en) | 2015-02-20 | 2018-07-10 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10632126B2 (en) | 2015-02-20 | 2020-04-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10251892B2 (en) | 2015-02-20 | 2019-04-09 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11014923B2 (en) | 2015-02-20 | 2021-05-25 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10214528B2 (en) | 2015-02-20 | 2019-02-26 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9801889B2 (en) | 2015-02-20 | 2017-10-31 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11173162B2 (en) | 2015-02-20 | 2021-11-16 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11667635B2 (en) | 2015-02-20 | 2023-06-06 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10214515B2 (en) | 2015-08-20 | 2019-02-26 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Substituted pyrazoles as inhibitors of fibroblast growth factor receptor |
US10544144B2 (en) | 2016-06-06 | 2020-01-28 | Shanghai Allist Pharmaceutical And Medical Technol | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof |
US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4056558A4 (en) * | 2019-11-06 | 2023-12-27 | Jinan University | Indazole compound, pharmaceutical composition of same, and applications thereof |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
WO2021138391A1 (en) * | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8268869B2 (en) | Vinyl indazolyl compounds | |
US8530665B2 (en) | Crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
JP5868992B2 (en) | Substituted benzopyrazine derivatives as FGFR kinase inhibitors for the treatment of cancer diseases | |
JP6363068B2 (en) | Pteridine as an FGFR inhibitor | |
JP6054406B2 (en) | Anti-cancer benzopyrazine via FGFR kinase inhibition | |
CN113307797B (en) | Polysubstituted quinazoline compound and application thereof | |
CN110903283A (en) | Substituted quinazoline compound, pharmaceutical composition containing compound and application of compound | |
CN115315422B (en) | Amide compound and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080020264.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10717402 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2067/MUMNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 595553 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010717402 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/011342 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 216004 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2760535 Country of ref document: CA Ref document number: 001877-2011 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 2010246114 Country of ref document: AU Date of ref document: 20100504 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117026320 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012509889 Country of ref document: JP Ref document number: 11150245 Country of ref document: CO |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000580 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201171367 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1013748 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2013/0207 Country of ref document: RS |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000013-2016 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: PI1013748 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111104 |